The postictal state is generally followed by antinociception. It is known that connections between the dorsal raphe nucleus, the periaqueductal gray matter, and the locus coeruleus, an important noradrenergic brainstem nucleus, are involved in the descending control of ascending nociceptive pathways. The aim of the present study was to determine whether noradrenergic mechanisms in the locus coeruleus are involved in postictal antinociception. Yohimbine (an α 2 -receptor antagonist) or propranolol (a β-receptor antagonist) was microinjected unilaterally into the locus coeruleus, followed by intraperitoneal administration of pentylenetetrazole (PTZ), a noncompetitive antagonist that blocks GABA-mediated Cl -influx. Although the administration of both yohimbine and propranolol to the locus coeruleus/subcoeruleus area resulted in a significant decrease in tonic or tonic-clonic seizure-induced antinociception, the effect of yohimbine restricted to the locus coeruleus was more distinct compared with that of propranolol, possibly because of the presynaptic localization of α 2 -noradrenergic receptors in locus coeruleus neurons. These effects were related to the modulation of noradrenergic activity in the locus coeruleus. Interestingly, microinjections of noradrenaline into the locus coeruleus also decrease the postictal antinociception. The present results suggest that the mechanism underlying postictal antinociception involves both α 2 -and β-noradrenergic receptors in the locus coeruleus, although the action of noradrenaline on these receptors causes a paradoxical effect, depending on the nature of the local neurotransmission.
Introduction
γ-Aminobutyric acid (GABA)-, acetylcholine-, serotonin-, and noradrenaline-mediated systems have often been implicated as neuronal bases of postictal analgesia and have been the subject of numerous studies concerning the neural basis of pain modulation [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The periaqueductal gray matter (PAG) and certain nuclei of the reticular formation are thought to be the main structures involved in supraspinal pain modulation [6, [10] [11] [12] [13] [14] [15] [16] . Reciprocal connections between the locus coeruleus (LC), situated on both sides of the median line [17] , and descending pathways from the LC are crucially involved in modulating the activity of ascending nociceptive pathways, which, in turn, can be modulated by serotonergic output from the dorsal raphe nucleus (DRN) to the dorsal horn of the spinal cord [18, 19] . These findings lead us to postulate that the LC represents a key structure in the organization of epilepsy-induced hypoalgesia.
Damage to noradrenaline-containing neurons in the LC converts episodic limbic seizures induced by bicuculline infusion in the anterior piriform cortex into self-sustaining status epilepticus [20] . Studying the roles of both α-and β-mediated LC mechanisms may elucidate the involvement of this important noradrenergic structure in postictal antinociception. Descending outputs from both LC and subcoeruleus (SC) neurons are known to be involved in the modulation of nociceptive transmission. In fact, activation of descending LC/SC neurons can produce profound antinociception [21, 22] , which may inhibit the nociceptive activity of spinal dorsal horn neurons [23] [24] [25] and trigeminal subnucleus caudalis neurons [17, 26] . West et al. [27] suggested that both electrical stimulation of and administration of morphine [28] into the LC have antinociceptive effects. The interplay between the LC and serotonergic brainstem nuclei [9, 17, 29] may also be important for the modulation of nociception. It follows that stimulation of the DRN [30] and PAG [12, [31] [32] [33] [34] [35] , both structures rich in serotonin-containing neurons and fibers [10, 36, 37] , causes intense antinociception. In fact, α 2 -adrenoceptors and 5-HT 1A somatodendritic autoreceptors have important regulatory functions and are involved in the interaction between serotonin and noradrenaline [38] . These autoreceptors may play key roles in modulating neurotransmission in the LC [39, 40] . In addition, there is evidence suggesting GABA A receptor-mediated modulation of brainstem serotonergic and noradrenergic functions, altering the firing rate of both the DRN [41] and the LC [42] .
The only evidence to date for the recruitment of both α 2 -and β-noradrenergic receptors in the context of postictal antinociception was obtained from peripheral administration of specific antagonists [9] . There is a lack of other studies suggesting the involvement of α 2 -and β-noradrenergic receptors in the organization and modulation of antinociceptive processes induced by brain epileptogenic activity. In this study, we took into account previous evidence suggesting the involvement of the LC in postictal antinociception [9] , as well as recent robust neuroanatomical findings suggesting reciprocal connections between neurons of the LC situated on both sides of the median line [17] . There are also several reports indicating that the LC noradrenergic system plays an important role in the descending modulation of spinothalamic ascending nociceptive pathways [6, 10, [43] [44] [45] . In this context, the present study focused on the role of presynaptic α 2− and postsynaptic β-noradrenergic receptors on LC neurons in the modulation of postictal antinociception, to better understand the oscillation of the postseizure nociceptive threshold, which is associated with the postictal immobility syndrome.
Materials and methods

Animals
We used male Wistar albino rats weighing between 200 and 250 g (n = 5-9 per group) from the animal care facility of the Ribeirão Preto Campus at the University of São Paulo (USP). The animals were housed in groups of four in plexiglass cages and given free access to food and water throughout the experiment. The room temperature was controlled (22 ± 1°C), and a light-dark cycle (07:00-19:00 hours lights on) was maintained. The experimental protocols were reviewed and approved (Proc. 074/2004) by the Ethics Commission in Animal Experimentation (CETEA) at FMRP-USP, and all experiments were performed in accordance with the recommendations of CETEA, based on the guidelines of the Brazilian Society for Neuroscience and Behaviour (SBNeC) and on the Animal Research Ethics standards adopted by the Brazilian College of Animal Experimentation (COBEA).
Surgical procedures
Animals were anesthetized with sodium xilasine (0.2 mL, ip) and ketamine (0.1 mL, ip) and fixed in a stereotaxic frame (David Kopf, USA). A stainless-steel guide cannula (o.d. 0.6 mm, i.d. 0.4 mm) was implanted unilaterally in the brainstem, aimed at the LC. The upper incisor bar was set 3.3 mm below the interaural line, such that the skull was horizontal between bregma and lambda. The guide cannula was vertically introduced using the following coordinates, with the bregma serving as the reference for each plane: anteroposterior, -9.68 mm; mediolateral, 1.4 mm; dorsoventral, 6 mm. The guide cannula was fixed to the skull using acrylic resin and two stainless-steel screws. At the end of the surgery, each guide cannula was sealed with a stainless-steel wire to prevent obstruction.
Nociceptive testing
Nociception thresholds were compared using the tail-flick test. Each animal was placed in a restraining apparatus (Stoelting) with acrylic walls, and its tail was placed in a heating sensor (tail-flick Analgesia Instrument; Stoelting, IL, USA), the progressive calorimetric elevation of which was automatically interrupted at the moment when the animal removed its tail from the apparatus. The current raised the temperature of the coil (Ni/Cr alloy; 26.04 cm in length × 0.02 cm in diameter) at a rate of 9°C/second [46] , starting at room temperature (approximately 20°C). If necessary, a small current intensity adjustment was made at the start of the experiment to obtain three consecutive tail-flick latencies (TFLs) between 2.5 and 3.5 seconds. If the animal did not remove its tail from the heater within 6 seconds, the apparatus was turned off to prevent skin damage. As there were no statistically significant differences between baseline characteristics of the experimental groups, all tail-flick latencies were normalized by an index of analgesia (IA) using the following formula:
Three control baseline TFL readings were taken at 5-minute intervals. TFLs were also measured following seizures elicited by the peripheral administration of pentylenetetrazole (PTZ).
Behavioral testing and seizure evaluation
Behavioral tests were performed by placing the rats in the interior of a circular arena with transparent acrylic walls. The arena measured 60 cm in diameter and 50 cm in height and was located in an experimental compartment illuminated by a fluorescent lamp (350 lx at arena floor level). The effects of drug administration (PTZ, yohimbine, propranolol, and physiological saline) were evaluated with the rats inside the arena.
Tonic or tonic-clonic convulsive reactions induced by PTZ (64 mg/kg, ip) served as the motor parameter that was used to evaluate the effect of the blockade of GABA-mediated Cl -influx.
Seizure latency was defined as the time between injection of PTZ and the first evidence of anterior paw myoclonia, which was considered to indicate the beginning of the seizure. The severity of the convulsive reactions was evaluated according to the following motor paramaters: index 0 = exploratory behavior; index 1 = jaw myoclonia and facial musculature myoclonia, forepaw myoclonia at short duration; index 2 = head myoclonia, moderate forepaw at short duration (at least 5 seconds); index 3 = forepaw and/or hindpaw severe musculature hypertonia, forepaw severe musculature hypertonia at intermediate duration (at least 10 seconds); index 4 = forepaw and/or hindpaw severe musculature hypertonia, rearing, and also forepaw severe myoclonia; index 5 = forepaw and/or hindpaw severe musculature hypertonia, rearing and falling, and also forepaw severe myoclonia. PTZ-induced convulsive reactions were recorded using a video camera (Panasonic, M3500) focused on the open field, and the VHS tapes (JVC, SX Gold) were subsequently evaluated to classify, characterize, and quantify the convulsive reactions.
Neuropharmacological procedures
Five days after surgery, a baseline tail-flick test was performed for each animal in a given group. Animals in the control group were removed from the box, placed in the open field, and observed for 15 minutes without drug injection. After this period, the animals were removed from the arena, and their nociceptive thresholds were standardized using the tail-flick test. After that, an independent group of animals received microinjections of physiological saline (0.2 or 0.5 μL, n = 7 or 8), yohimbine (at 1.0 μg/0.2 μL, n = 7, 3.0 μg/0.2 μL, n = 5, 5.0 μg/0.2 μL, n = 9, or 5.0 μg/0.5 μL, n = 8), propranolol (at 1.0 μg/0.2 μL , n = 8, 3.0 μg/0.2 μL, n = 7, 5.0 μg/0.2 μL, n = 9, or 5.0 μg/0.5 μL, n = 8), or norepinephrine (at 1.0 μg/0.2 μL, n = 8, 3.0 μg/0.2 μL, n = 5, 5.0 μg/0.2 μL, n = 6) into the LC. The microinjections were done using a thin dental needle (Mizzy, o.d. 0.3 mm) introduced through the guide cannula until its lower end extended 1 mm below the guide cannula. The needle was left in place for an additional 1 minute after the injection. Ten minutes later, the animals received PTZ (64 mg/kg, ip), and nociceptive responses were evaluated immediately after the tonic/tonic-clonic seizures and in the subsequent postictal period from 10 to 180 minutes.
As a control of the eventual intrinsic effect of LC neurons on the baseline nociceptive thresholds, additional experiments were performed with the following procedures: (1) microinjection of ibotenic acid (at 1.0 μg/0.2 μL) into the LC followed by intraperitoneal administration of physiological saline; (2) microinjection of ibotenic acid (at 1.0 μg/0.2 μL) into the LC followed by intraperitoneal administration of PTZ; (3) sham procedure (introduction of an injector needle into the guide cannula inserted in the LC without local microinjection of the neurotoxin) followed by intraperitoneal administration of PTZ.
Drugs
Pentylenetetrazole (Sigma/Aldrich, St. Louis, MO, USA), yohimbine (Sigma), propranolol (Sigma), norepinephrine (Sigma), and ibotenic acid (Sigma) were each dissolved in physiological saline (NaCl 0.9%) shortly before use. Drugs were administered at the following concentrations/doses: yohimbine and propranolol ( 
Histological analysis
After testing, the rats were anesthetized with sodium pentobarbital (45 mg/kg, ip) and perfused via the left ventricle. The blood was washed out with cold, oxygen-enriched, Ca 2+ -free Tyrode's buffer (40 mL at 4°C), followed by 200 mL of ice-cold 4% (w/v) paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.3, for 15 minutes at a pressure of 50 mm Hg. The brainstem was quickly sectioned, removed, and immersed in fresh fixative for 4 hours at 4°C. It was then rinsed in 10 and 20% sucrose dissolved in 0.1 M sodium phosphate buffer (pH 7.4) at 4°C, for at least 12 hours in each solution. Tissue pieces were immersed in 2-methylbutane (Sigma), frozen on dry ice, embedded in Tissue Tek OCT, and cut with a cryostat (HM 505 Microm, Zeiss) at −22°C. Sections were then mounted on glass slides coated with chrome alum gelatin to prevent detachment and stained with hematoxylin-eosin to be viewed on a photomicroscope (AxioImager Z1, Zeiss). Statistical analysis was performed exclusively with data from the animals that presented signs of microinjections of the drugs into the LC.
Analysis of results
Data from experiments to investigate the effect of seizures on nociceptive threshold and the effect of neurotoxic lesions of the LC on TFLs as well as on postictal antinociception, the involvement of α 2 -and β-receptor mediated noradrenergic mechanisms, and the role of norepinephrine-mediated neurotransmission in postictal antinociception were submitted to a repeated-measures analysis of variance (ANOVA). In case of a significant treatment versus time interaction, one-way ANOVA was performed at each time interval, followed by Duncan's post hoc test. P b 0.05 was indicative of statistically significant differences.
Results
Wistar rats that had been intraperitoneally administered with PTZ at 64 mg/kg exhibited distinct types of motor seizures-orofacial Table 1 Severity of generalized tonic-clonic convulsive reactions induced by intraperitoneal administration of PTZ at 64 mg/kg.
Treatment
Latency ( between the physiological saline-, yohimbine-and propranololpretreated groups (Table 1A) . Fig. 1 is a photomicrograph Fig. 2 . The site of each drug microinjection was situated in the LC (Fig. 3) .
Both treatments were also conducted using a smaller volume of each solution. There were no statistically significant differences in latency to [F(3,24) = 1. (Table 1B) .
Also, there were no statistically significant differences in the latency to [F(3,27) = 1. (Table 1C) .
Furthermore, treatment with a nonspecific agonist was performed. There were no statistically significant differences in the latency to [F(3,23) = 2. were statistically significant differences in duration [F(3,23) = 12.02, P = 0.0001] of each PTZ-induced seizure between the physiological saline-and norepinephrine-pretreated groups (Table 1D) Duncan's post hoc test (P b 0.05) showed that blockade of α 2 -noradrenergic receptors in the LC caused a statistically significant decrease in postictal antinociception. These data are illustrated in Fig. 4 . All sites studied were situated in the LC (Fig. 5) .
In showed that blockade of β-noradrenergic receptors in the LC caused a statistically significant decrease in postictal antinociception. These data are illustrated in Fig. 6 . All sites studied were situated in the LC (Fig. 7) .
Administration of the nonspecific agonist norepinephrine in the LC caused an interesting depressed effect on postictal antinociception. Duncan's post hoc test (P b 0.05) showed that norepinephrine on noradrenergic receptors in the LC caused a statistically significant decrease in postictal antinociception. These data are illustrated in Fig. 8 . All sites studied were situated in the LC (Fig. 9) .
These effects were independent of epileptic seizures induced by blockade of GABA-mediated Cl − influx, given that central administration of yohimbine or propranolol at major concentrations (5.0 μg/0.5 μL) targeted to the LC did not cause any statistically significant effect on the nociceptive threshold (P N 0.05 in all cases, as compared with the control). Thus, both noradrenergic antagonists Moreover, it was shown that the LC neutotoxic lesion alone was not able to cause any significant change in baseline TFLs. Duncan's post hoc test also showed statistically significant differences between the group pretreated with ibotenic acid in the LC followed by IP treatment with PTZ, and the group pretreated with ibotenic acid in the LC followed by IP treatment with physiological saline immediately after seizures and from 10 to 60 minutes after tonic-clonic convulsions. These data are illustrated in Fig. 12 . The site of each microinjection procedure was situated in the LC (Fig. 13 ).
Discussion
In the present study, PTZ-induced tonic-clonic seizures were accompanied by statistically significant antinociception. The present results demonstrate the involvement of LC neurons in the organization of postictal antinociception, considering that neurochemical lesion of the LC neurons decreased the elevation of nociceptive thresholds after tonic-clonic seizures, but not the baseline TFLs. In addition, the present work provides evidence for a paradoxical involvement of both presynaptic α 2 -autoreceptors and postsynaptic β-noradrenergic receptors in the LC in the mechanism of postictal antinociception. This is the first presentation of evidence regarding the involvement of noradrenergic receptors in the LC in antinociceptive phenomena caused by seizures. Interestingly, recent findings have demonstrated that α-and β-noradrenergic receptors participate in other kinds of hypoalgesia [47, 48] .
Peng et al. [49] showed that microinjections of yohimbine into the dorsal horn of the spinal cord antagonize the antinociception induced by electrical stimulation of the PAG. Expression of α 2 -noradrenergic receptor mRNA in noradrenergic neurons in a previous study [50] , however, indicated that this receptor subtype mediates presynaptic autoreceptor function. We expected that blockade of this noradrenergic receptor in the LC would increase postictal antinociception, given that the inhibition of adenylyl cyclase activity, which results in decreased formation of cAMP, is an important consequence of α 2 -noradrenergic receptor activation [51] . The paradoxical effect of α 2 -noradrenergic receptor blockade on postictal antinociception could be easily explained by interactions with inhibitory neurons (e.g., using GABA-mediated neurotransmission) modulating the activity of LC noradrenergic outputs. In fact, a previous neuromorphological study showed evidence of the presence of GABAergic neurons in the LC [52, 53] , and LC noradrenergic neurons are immunoreactive for the α 2 and α 3 GABA A receptor subunits [54] . In addition, there is evidence suggesting the existence of a subpopulation of small GABAergic neurons in the peri-LC dendritic zone, which provide interneuronal integration for LC noradrenergic neurons [42] . This could explain the reduction in the postictal antinociception curve when yohimbine was administered centrally in a large volume, possibly involving neurons in the peri-LC dendritic zone.
Interestingly, some β-noradrenergic receptor antagonists have been shown to have local anesthetic effects [55] [56] [57] . Together with its classic nonselective β-noradrenergic receptor antagonist effect, it has been accepted that propranolol inhibits high-voltage activated Ca 2+ currents and a low-voltage activated Ca 2+ current [58, 59] at low concentrations and moderately suppresses potassium currents at high concentrations [60] . In the present study, we can consider the effects of propranolol on LC neurons to be due to β-noradrenergic receptor antagonism, given that there was no intrinsic effect of central pretreatment with propranolol on baseline TFLs. Surprisingly, pretreatment of the LC with norepinephrine also decreased postictal antinociception, suggesting a paradoxical effect of norepinephrine-mediated neurotransmission into the LC on antinociceptive outputs from this nucleus. The LC can modulate pain through classic noradrenergic descending pathways [25, 61] , but its influence on nociceptive stimuli perception can be processed through an ascending pathway connecting somatosensorial and parafascicular thalamic nuclei [62, 63] . Ascending projections from the LC exert a dual role at the medial thalamus, acting on parafascicular nucleus with both facilitatory and inhibitory mechanisms through, respectively, α 1 -and α 2 -noradrenergic receptors [63] .
Interestingly, Zhang et al. [64] showed that depending on the dose, administration of norepinephrine in the neostriatum is followed by either antinociception (at lower doses) or pronociception (at higher doses). Another possible explication for these Fig. 4 . Effect of microinjection of yohimbine (at 1 μg/0.2 μL, n =7, 3 μg/0.2 μL, n =5, or 5 μg/0.2 μL, n = 9) in the LC nucleus on postictal antinociception. Data are presented as means ± SEM. *Statistically significant difference (P b 0.05) compared with the group treated with physiological saline (n = 6) followed by intraperitoneal injection of PTZ at 64 mg/kg. + Statistically significant difference (P b 0.05) compared with the group treated with 1 μg/0.2 μL yohimbine in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg, § Statistically significant difference (P b 0.05) compared with the group treated with 5 μg/0.2 μL yohimbine in the LC followed by intraperitoneal injection of PTZ at 64 mg/kg, based on repeated-measures ANOVA followed by Duncan`s post hoc test.
findings could be an inhibitory feedback mechanism exerted on presynaptic α 2 -noradrenergic receptors, or even on postsynaptic α 1 -noradrenergic receptors, already implicated in facilitatory mechanisms of pain [65] .
In addition, there is other evidence suggesting that the effect of norepinephrine on noradrenergic receptors can effectively either facilitate or inhibit nociceptive reflexes. Several behavioral in vivo studies showed that microinjection of an α 2 -noradrenergic receptor agonist or an α 1 -noradrenergic receptor antagonist in the nucleus raphe magnus causes spinal antinociceptive effects, whereas injections of α 1 -or α 2 -noradrenergic receptors agonists cause hyperalgesic effects [66] . It is known that the action of norepinephrine on α 2 -noradrenergic presynaptic receptors decreases about 90% of its own continuous release on noradrenergic synapses, promoting negative feedback. The α 2 -noradrenergic receptor agonist clonidine, at higher doses, inhibits the release of norepinephrine through the same negative feedback mechanism in the dorsal horn of the spinal cord [67] . In addition, according to Green et al. [68] , under normal conditions, the noradrenergic inhibitory feedback system can be nonresponsive, whereas under pathophysiological conditions it is commonly active. In a peripheral neuritis experimental model, injection of norepinephrine worsened the mechanical hyperalgesia, and this was attenuated not only by an α 2 -noradrenergic receptor antagonist, but also by an α 1 -noradrenergic receptor antagonist [69, 70] . In addition, several studies indicate that the LC is recruited by damaging nociceptive stimuli, inflammation, or nerve lesion by promoting inhibitory feedback of pain [71, 72] . However, although there are studies showing the involvement of α 2 -noradrenergic receptors in norepinephrine-induced pain, there is also behavioral and neurophysiological evidence suggesting the involvement of α 1 -noradrenergic receptors in the facilitation of pain [70] . These findings suggest a role for LC (direct or indirectly via other structures of the brainstem) in the facilitation of pain in distinct pathophysiological processes, such as neuropathic pain [73] or postischemic chronic pain [74] . In humans, injection of norepinephrine into the tegument was found to cause hyperalgesia to heat [75] .
Supraspinally, the norepinephrine effect on noradrenergic receptors can both facilitate and inhibit pain depending on the supraspinal site of its release, the type of receptor subfamily activated, and the intensity and duration of painful stimuli [70] . In line with this evidence, it has been postulated that α 2 -noradrenergic receptors situated on noradrenergic neurons (autoreceptors) cause pronociception, whereas these same receptors situated on non-noradrenergic neurons (heteroreceptors) cause antinociception [70] .
We cannot, however, rule out the possibility of involvement of other mechanisms in the elaboration of postictal antinociception. In fact, endogenous opioid peptide-, acetylcholine-, serotonin-, and norepinephrine-mediated systems have been implicated in the organization of tonic-clonic seizure-induced antinociception [9, [76] [77] [78] .
Yohimbine microinjected (at lower concentration) into the LC has also increased the duration of convulsive reactions, but this pretreatment did not modify the severity index of seizures. Intra-LC pretreatment with propranolol at the lower concentration caused an effect similar to that of yohimbine: increasing the duration of convulsive reactions, but exerting no effect on the severity of convulsive seizures. There is evidence in the literature that both yohimbine and propranolol modulate convulsive activity [79] . In the present work norepinephrine, at peak concentrations, increased the duration of PTZ-induced seizures as evidenced by noradrenergic antagonists such as yohimbine and propranolol.
Interestingly, it seems that norepinephrine has a dual effect on convulsive responses, modulating or mediating the elaboration of this motor phenomenon [79] . In addition to its role in the elaboration/ modulation of postictal antinociception, it is possible that norepinephrine also exerts some effect through α 1 -noradrenergic receptors in the elaboration of convulsive responses.
Despite the evidence that the monoaminergic system is crucial to convulsive reactions [80] [81] [82] [83] [84] [85] , the LC is considered to be a key structure involved in the modulation of brain epileptic activity [20, 86] , and bilateral lesions of the LC facilitate audiogenic seizures [87] . These data may indicate that the LC exerts a relevant role in postictal antinociceptive responses. Indeed, recent reports suggest that LC neurons play an important role in determining immediate early gene expression, even under conditions of strong pathological activation such as limbic status epilepticus [88, 89] , and that neurochemical lesion of the LC decreases postictal analgesia [9] . The present work corroborates these findings and, further, suggests involvement of the LC noradrenaline-mediated system in the organization of postictal antinociception. In summary, a decrease in LC activity impairs postictal antinociception. Antagonism of the increased nociceptive threshold caused by seizures in all postictal periods was attenuated either by the direction/indirect action of norepinephrine or by the blockade of α 2− or β-noradrenergic receptors in LC neurons prior to tonic-clonic seizure-induced analgesia, strongly supporting a role for the involvement of noradrenergic pathways and α 2 -and β-noradrenalinemediated LC mechanisms in the organization and modulation of postictal antinociception. 
